we can expect breaks between cohorts as safety dat

we can expect breaks between cohorts as safety data etc... is reviewed.

Now - I'm getting a little wild in my speculation of what ctix may have done with sk. So - this is me playing and not meant to be taken seriously at all.

What if.....they are pretty confident in both lack of toxicity and efficacy of kevetrin....and are planning a piggyback product. Piggyback product has component that protects cells during chemo and product that is cancer killer. It can be combined with chemo regimens as efficacy adjunct and chemoprotective agent....It could go anywhere...

Just playin! Love to speculate sometimes - but that's all this is!